Multiple putative cardiovascular-related pathways without validated direct molecular targets

This designation refers to therapeutic interventions or biological processes that influence cardiovascular physiology without a validated, direct molecular target, such as a specific receptor or enzyme. This scenario is common in phenotypic drug discovery (PDD), where drugs are developed based on their ability to produce a desired physiological outcome in complex biological systems rather than their affinity for a pre-selected protein (Moffat et al., 2017). Such mechanisms may involve polypharmacology, where the observed effect results from the modulation of multiple pathways simultaneously, or they may involve novel targets that have not yet been identified through traditional biochemical methods (Swinney & Anthony, 2011). For drug development, this lack of a defined target presents significant hurdles, including the inability to use structure-based drug design and challenges in predicting off-target toxicities. Target deconvolution—the process of identifying the specific molecular targets of these compounds—is a critical step in transitioning these observations into structured drug discovery programs (Terstappen et al., 2007). Until a target is validated, these pathways remain characterized by their systemic outcomes, such as changes in blood pressure, heart rate, or vascular resistance. This category is often used in pharmacological databases to flag compounds with known efficacy but unknown molecular pharmacology. As research techniques like chemical proteomics and high-content imaging advance, many of these pathways are eventually resolved into specific molecular targets. For biotech analysts, this category represents a high-risk area of drug development where the primary challenge lies in identifying the molecular entity responsible for the therapeutic effect. Establishing a clear mechanism of action is often a prerequisite for modern regulatory approval and clinical differentiation.

Other names

Unknown/Multiple putative cardiovascular-related pathways without validated direct molecular targetsUncharacterized cardiovascular pathwaysNon-specific cardiovascular mechanismsPhenotypic cardiovascular effects

The mechanism of action involves modulation of cardiovascular physiology through pathways that have not yet been mapped to a single, validated molecular target such as a specific receptor or enzyme.